Minerva Biotechnologies

Minerva Biotechnologies, founded in 1999, is a clinical stage biopharmaceutical company headquartered in the United States. The company focuses on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. Their pioneering approach involves the NCT04020575 trial of huMNC2-CAR44, a groundbreaking CAR T therapy targeting the MUC1* growth factor receptor, specifically designed for treating metastatic breast cancers, 95% of which express MUC1*. The company is currently expanding this trial to include a second CAR-T product aimed at significantly increasing persistence. In addition, Minerva Biotechnologies is rapidly advancing its pipeline, which includes next-gen CAR-T products, a straight antibody therapeutic, and a small molecule therapeutic, all focusing on combatting cancer metastasis. Despite the challenges in the biotechnology sector, the company's track record of scientific breakthroughs is a testament to its visionary team and collaborative culture. The latest investment received by Minerva Biotechnologies was a Venture - Series Unknown investment on 05 December 2023, showcasing the confidence that investors have in the company's innovative approach to transforming the landscape of cancer treatment and regenerative medicine.